The calm before the storm: A report from the International Liver Cancer Association Congress 2015 - Part 1

Future Oncology

Volumn 12, Issue 3, 2016, Pages 281-284

  Cabibbo, Giuseppe ^a   Reig, Maria ^b,c   Gadaleta Caldarola, Gennaro ^d   Galati, Giovanni ^e   Lombardi, Giuseppe ^f   Mazza, GianCarlo ^g   Marzi, Luca ^h   Saitta, Carlo ⁱ   Nault, Jean Charles ^j,k,l   Sacco, Rodolfo ^m  

^a UNIVERSITY OF PALERMO   (Italy)

^b UNIVERSITY OF BARCELONA   (Spain)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

^d Division of Oncology   (Italy)

^e UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^f VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^g Spedali Civili ^*  (Italy)

^h UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

ⁱ UNIVERSITY OF MESSINA   (Italy)

^j ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^k INSERM   (France)

^l UNIVERSITÉ PARIS 13   (France)

^m UNIVERSITY HOSPITAL OF PISA   (Italy)

more..

Author keywords

HCC; immunotherapy; liver cancer; prognosis; sorafenib; staging system; survival; trial design

Indexed keywords

CANCER RADIOTHERAPY; CANCER STAGING; CONFERENCE PAPER; FRANCE; HUMAN; IMMUNOTHERAPY; LIVER CANCER; LIVER CELL CARCINOMA; NON PROFIT ORGANIZATION; PRIORITY JOURNAL; DISEASE MANAGEMENT; LIVER TUMOR;

CARCINOMA, HEPATOCELLULAR; DISEASE MANAGEMENT; HUMANS; LIVER NEOPLASMS;

EID: 84961389377     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.15.323     Document Type: Conference Paper

References (21)

1. Gores GJ. Significance of mixed hepatocellular - cholangiocarcinoma. Presented at: The International Liver Cancer Association 2015 Annual Conference. Paris, France, 4-6 September 2015
2. Cabibbo G, Enea M, Attanasio M, et al. A meta-analysis of survival rates of untreated patients in randomized clinical trials of hepatocellular carcinoma. Hepatology 51(4), 1274-1283 (2010
3. Villa E, Critelli R, Lei B, et al. Neoangiogenesis-related genes are hallmarks of fast-growing hepatocellular carcinomas and worst survival. Results from a prospective study. Gut doi: 10.1136/gutjnl-2014-308483 (2015) (Epub ahead of print
4. Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int. J. Cancer 136(5), E359-E386 (2015
5. Fong ZV, Tanabe KK. The clinical management of hepatocellular carcinoma in the United States, Europe, and Asia: a comprehensive and evidence-based comparison and review. Cancer 120(18), 2824-2838 (2014
6. Bruix J, Poon R. BCLC is the gold standard. Presented at: The International Liver Cancer Association 2015 Annual Conference. Paris, France, 4-6 September 2015
7. Yau T, Tang VY, Yao TJ, et al. Development of Hong Kong Liver Cancer staging system with treatment stratification for patients with hepatocellular carcinoma. Gastroenterology 146(7), 1691-1700 (2014
8. Yang T, Tabrizian P, Lu JH, et al. Comparisons of outcomes after liver resection for hepatocellular carcinoma between the east and the west: a propensity score matching analysis. Presented at: The International Liver Cancer Association 2015 Annual Conference. Paris, France, 4-6 September 2015
9. Reig M, Darnell A, Forner A, Rimola J, Ayuso C, Bruix J. Systemic therapy for hepatocellular carcinoma: the issue of treatment stage migration and registration of progression using the BCLC-refined RECIST. Semin. Liver Dis. 34(4), 444-455 (2014
10. Raoul JL, Sangro B, Forner A, et al. Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: available evidence and expert opinion on the use of transarterial chemoembolization. Cancer Treat. Rev. 37(3), 212-220 (2011
11. Cabibbo G, Tremosini S, Galati G, et al. Transarterial chemoembolization and sorafenib in hepatocellular carcinoma. Expert Rev. Anticancer Ther. 14(7), 831-845 (2014
12. Bolondi L, Burroughs A, Dufour JF, et al. Heterogeneity of patients with intermediate (BCLC B) hepatocellular carcinoma: proposal for a subclassification to facilitate treatment decisions. Semin. Liver Dis. 32(4), 348-359 (2012
13. Sieghart W, Hucke F, Pinter M, et al. The ART of decision making: retreatment with transarterial chemoembolization in patients with hepatocellular carcinoma. Hepatology 57(6), 2261-2273 (2013
14. Maida M, Orlando E, Cammà C, Cabibbo G. Staging systems of hepatocellular carcinoma: a review of literature. World J. Gastroenterol. 20(15), 4141-4150 (2014
15. Cabibbo G, Genco C, Di Marco V, et al. Predicting survival in patients with hepatocellular carcinoma treated by transarterial chemoembolisation. Aliment. Pharmacol. Ther. 34(2), 196-204 (2011
16. Reig M, Rimola J, Torres F, et al. Postprogression survival of patients with advanced hepatocellular carcinoma: rationale for second-line trial design. Hepatology 58(6), 2023-2031 (2013
17. Iavarone M, Cabibbo G, Biolato M, et al. Predictors of survival in patients with advanced hepatocellular carcinoma who permanently discontinued sorafenib. Hepatology 62(3), 784-791 (2015
18. Ogasawara S, Chiba T, Ooka Y, et al. Impact of post-progression survival in sorafenib-failed patients with advanced hepatocellular carcinoma. Presented at: The International Liver Cancer Association 2015 Annual Conference. Paris, France, 4-6 September 2015
19. Kalogeridi MA, Zygogianni A, Kyrgias G, et al. Role of radiotherapy in the management of hepatocellular carcinoma: a systematic review. World J. Hepatol. 7(1), 101-112 (2015
20. Tsutsumi T, Nagamatsu H, Mizukami N, et al. Evaluation of radiotherapy for patients with unresectable advanced hepatocellular carcinoma. Presented at: The International Liver Cancer Association 2015 Annual Conference. Paris, France, 4-6 September 2015
21. Yoon HI, Jung I, Kim MS, et al. The effect of radiotherapy in liver-confined but non resectable BCLC stage C hepatocellular carcinoma: propensity-matched analysis based on nationwide multicenter HCC cohort. Presented at: The International Liver Cancer Association 2015 Annual Conference. Paris, France, 4-6 September 2015